ArticleCancer management and research2022

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (

Ziyi Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.